Lantern Pharma Inc.LTRN
Price (close)
$1.21
Market cap
$15.4M
P/E
—
Revenue (TTM)
—
Net income
-$18.7M
Dividend yield
—
1-year total return
-72.1%
Net margin
—
Revenue growth
—
Debt / equity
—
What Lantern Pharma Inc. does.
are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline
of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates
and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$5.9M | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Free cash flow | — | -$10.6M | -$12.8M | -$14.4M | -$17.8M | -$15.7M |
More on LTRN.
- Lantern Pharma Inc. summary
- Lantern Pharma Inc. financial statements
- Lantern Pharma Inc. key metrics
- Lantern Pharma Inc. health scores and style box
- Lantern Pharma Inc. earnings
- Lantern Pharma Inc. dividends
- Lantern Pharma Inc. valuation
- Lantern Pharma Inc. ownership and insiders
- Lantern Pharma Inc. peers
Figures from Lantern Pharma Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.